Context: Hypogonadism is highly prevalent among obese men with metabolic syndrome. Chronic low-grade inflammation is suspected to be a major cause for low testosterone levels in obese individuals.
S
everal epidemiological studies have shown a high prevalence of low testosterone levels in men with metabolic syndrome (1) (2) (3) . Consequently, testosterone prescriptions have increased substantially within the last decades. However, the risk/benefit ratio of such treatment is highly controversial, especially in view of conflicting data on cardiovascular outcomes (4) . Alternative treatment strategies are desirable.
There is evidence for a marked inverse association between the degree of obesity, states of insulin resistance, and serum testosterone concentrations (5) (6) (7) (8) . Chronic low-grade inflammation may be a fundamental determinant of that interplay (9) (10) (11) .
IL-1b is a cytokine that is a key component in the activation of the innate immune system (12) . Previous studies have shown that IL-1 antagonism improves glycemia and b-cell secretory function and reduces markers of systemic inflammation such as IL-6 and C-reactive protein (CRP) in patients with type 2 diabetes (13, 14) . In patients with chronic low-grade inflammation, IL-1b antagonism reduced the composite primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in a large randomizedcontrolled trial (15) .
However, to date no clinical trial has targeted inflammation with the aim of enhancing the endogenous testosterone production.
Material and Methods

Study design and participants
This is a placebo-controlled, double-blind, parallel-group, randomized trial at two centers in Switzerland involving 70 men who were recruited from January 2016 to June 2017. Patients received either twice-daily recombinant human IL-1 receptor antagonist [200 mg of anakinra (Kineret ® ) per day] or placebo for 4 weeks. Efficacy was assessed at baseline and after 1 day, 1 week, and 4 weeks, respectively. Data on adverse events were collected during the treatment period and for 2 months thereafter.
The conduct of the trial adhered to the Declaration of Helsinki and Good Clinical Practice guidelines, and ethics committees of participating hospitals approved the study before patient recruitment. The trial was registered on ClinicalTrials. gov (no. NCT02672592).
Main eligibility criteria were men aged 18 to 75 years, at least two serum morning total testosterone levels ,12 nmol/L (346 ng/dL) in fasting state, a body mass index (BMI; the weight in kilograms divided by the square of the height in meters) .30 kg/m 2 , and at least one of the following additional parameters of the metabolic syndrome: hyperglycemia (glycated hemoglobin .5.7% or 39 mmol/mol), hypertension (blood pressure .130/85 mm Hg or treatment of hypertension), or dyslipidemia [high-density lipoprotein (HDL) ,1.0 mmol/L, triglycerides .1.7 mmol/L, low-density lipoprotein (LDL) .3.4 mmol/L, or lipid-lowering treatment]. The trial excluded from enrollment patients with previous or current testosterone treatment, primary or secondary hypogonadism of other etiology, antiandrogen medication, drug abuse, infection during the last 2 months, or an immunocompromised state. Complete inclusion and exclusion criteria are outlined in the Supplemental Appendix (section A).
Randomization and masking
Eligible patients were randomly assigned (1:1 ratio) to receive 100 mg of the recombinant human IL-1 receptor antagonist anakinra, purchased by Swedish Orphan Biovitrum, or an identically appearing placebo twice daily, as self-administered, subcutaneous injections for 4 weeks. Randomization was done with variable block sizes of four to six. Allocation was concealed with a prespecified computer-generated randomization list, which was centrally kept at the Hospital Pharmacy, University of Basel Hospital.
Patients were randomly assigned to receive a set of study medication that was prepared prior to the initiation of the study and packed into identical containers according to the randomization list by the Hospital Pharmacy, University of Basel Hospital. Patients, treating physicians, investigators, and data assessors were masked to treatment allocation.
Procedures
All patients provided written informed consent. Compliance to treatment was assessed by counting returned empty syringes, by keeping a medication diary, and by measurement of plasma IL-1 receptor antagonist concentrations at 4 weeks.
All patients attended a screening visit where an investigator checked medical records and performed a physical examination and a blood sampling. At baseline, 4 weeks, and at follow-up, a body impedance analysis was performed and grip strength was measured by using a Jamar dynamometer, following a standardized protocol (16) . At baseline, 1 week, 4 weeks, and at follow-up, patients filled out three questionnaires: the severity of symptoms of hypogonadism was assessed with the quantitative androgen deficiency in the aging male (qADAM) questionnaire, which has a total score between 10 and 50, with 10 being most symptomatic and 50 being least symptomatic (17) . Treatment-related changes in male sexual function were assessed with the international index of erectile function (IIEF), a validated, 15-item questionnaire that assesses five domains of sexual function, including erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall sexual satisfaction (possible range of 5 to 75; higher scores representing better function) (18) . Mental and physical fatigue was assessed using the fatigue scale for motor and cognitive functions (FSMC) questionnaire (range, 20 to 100, with higher scores indicating higher severity of fatigue symptoms) (19) . A detailed study flowchart is drawn in the Supplemental Appendix (section E).
Routine clinical laboratory tests were performed locally at both participating centers. At the end of the trial, the serum concentrations of total testosterone, estradiol, and further parameters were measured in serum samples frozen at 280°C. CRP was determined with an immunoturbidimetric assay (Tinaquant CRP Gen.3 test, Roche Diagnostics, Mannheim, Germany). Prolactin was determined with an electrochemiluminescence immunoassay (ECLIA) (Elecsys prolactin II test, Roche Diagnostics). LH and FSH were determined with an ECLIA (Elecsys LH and FSH test, Roche Diagnostics). Sex hormone-binding globulin (SHBG) was measured using an ECLIA (Elecsys SHBG test, Roche Diagnostics). Steroid assays were performed at the central laboratory unit of one participating center (Kantonsspital Aarau, Aarau, Switzerland) by liquid chromatography with tandem mass spectroscopy [for a detailed description see Supplemental Appendix (section B)].
Outcomes
The predefined primary endpoint was the change in the morning total testosterone level between baseline and 4 weeks. Predefined secondary endpoints of laboratory parameters included changes in calculated free testosterone, SHBG levels, estradiol levels, LH/FSH ratio, prolactin levels, and in CRP levels. Predefined secondary endpoints of clinical variables included changes in IIEF score, FSMC score, qADAM score, blood pressure, and hand grip, respectively.
Statistical analysis
Our sample size calculation was based on preliminary data (20) assuming an increase in total testosterone levels from baseline to 4 weeks by 2 nmol/L (SD 6 2.0) in patients treated with the IL-1b antagonist anakinra compared with 0.5 nmol/L increase (SD 6 2.0) in patients receiving placebo. Inclusion of 64 participants was needed to give this study a power of 85% to show a significant difference in testosterone levels at an a error of 0.05. Assuming a dropout rate of 10%, we aimed to include a total of 70 patients. Following the intention-to-treat principle, all patients receiving at least one dose of study medication were included in the analysis with group allocation as randomized; patients violating inclusion criteria or meeting exclusion criteria due to information that was not available at study entry were excluded after randomization in a blinded manner (21) .
Categorical variables are expressed as counts (percentage) and continuous variables as means (6SD) unless stated otherwise. We used a linear regression (analysis of covariance) model adjusted for the baseline value of the dependent variable to investigate changes in testosterone levels (primary endpoint) and other secondary outcomes. Changes within each group were tested with the use of a paired t test and with a Wilcoxon signed rank test in case of nonnormal distribution, respectively. Predefined subgroup analyses with calculation of interaction terms were performed based on baseline CRP levels of #2 mg/L or .2 mg/L; baseline BMI #40 kg/m 2 or .40 kg/m 2 , or on the basis of achieving on-treatment reductions in CRP at 1 week of .1 mg/L or ,1 mg/L. Treatment comparisons for the occurrence of adverse events were analyzed with the Fisher exact test. All P values are two-sided and have not been adjusted for multiple testing. All CIs are at the 95% level. Statistical analyses were performed using STATA 14.2 (Stata Corp, College Station, TX), and graphs were drawn with GraphPad Prism 7.3 (GraphPad Software, La Jolla, CA).
Role of the funding source
The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of the report. F.E., P.S., and M.C.-C. had full access to all data in the study and had final responsibility for the decision to submit for publication.
Results
Patient characteristics
In total, 198 patients were screened. Of these, 128 did not fulfill the eligibility criteria or denied participation. Of 70 men who were enrolled, 67 (33 receiving anakinra treatment and 34 receiving placebo) completed the study and were available for the primary analysis ( Fig. 1) .
Clinical and demographic baseline characteristics were well balanced between treatment groups (Table 1) (22) . The mean age was 54 6 14 years, mean BMI was 36.8 6 4 kg/m 2 , 24% of the patients had type 2 diabetes mellitus, and 27% suffered from prediabetes, 71% from hypertension, and 83% from dyslipidemia. The mean baseline total testosterone level was 9.3 6 2.5 nmol/L, and CRP levels were 4.5 6 6.3 mg/L. Patients completing the trial were similar in their baseline testosterone levels and BMI to those who did not complete the trial.
Primary endpoint
The average absolute difference in total testosterone levels from baseline to 4 weeks was an increase of 1.2 nmol/L (from 9.0 6 2.4 to 10.2 6 2.8) in the anakinra group, as compared with a change of 0.01 nmol/L (from 9.6 6 2.6 to 9.6 6 2.4) in the placebo group, yielding a between-group difference of 0.96 nmol/L (95% CI, 0.29 to 1.89; P = 0.04) ( Fig. 2A ; Table 2 ).
When the patients were stratified into two groups according to baseline inflammatory state, those with a baseline CRP level .2.0 mg/L had a significantly higher between-group increase in total testosterone levels of 2.14 nmol/L (95% CI, 0.11 to 4.17; P = 0.04, n = 48) for anakinra-treated patients, as compared with men with lower inflammation at baseline (Fig. 2C) . The proportions of individuals achieving an on-treatment decrease of CRP levels of .1 mg/L after 1 week were 25 (76%) of 33 patients in the anakinra group, compared with 3 (11%) of 34 patients in the placebo group. Patients allocated to anakinra who achieved a CRP reduction of .1 mg/L after 1 week had a 2.8 nmol/L (95% CI, 20.028 to 5.38; P = 0.03) higher increase in testosterone levels at 4 weeks, whereas no significant benefit was observed among those with less pronounced CRP reductions (P = 0.85) (Fig. 2B) . Similarly, men with a BMI .40 kg/m 2 had a more pronounced increase of 2.64 nmol/L in testosterone levels as compared with those with lower BMI (95% CI, 0.19 to 5.09; P = 0.04, n = 11) (Fig. 2D ). The increase in testosterone was dependent on the age of the participants. An age ,65 years was associated with a significantly more pronounced increase by 2.10 nmol/L in total testosterone levels compared with older participants (95% CI, 0.03 to 4.18; P = 0.047, n = 49) (see Supplemental Fig. 2 ).
Secondary endpoints: laboratory variables
Markers of systemic inflammation Anakinra treatment led to a rapid and significant reduction of CRP levels already after 1 day, which was sustained during the course of 4 weeks, resulting in a difference of 2.29 mg/L (95% CI, 24.87 to 0.29) at 4 weeks compared with placebo. (Table 2 ; Supplemental Appendix; Supplemental Table 1 ). Levels of IL-6 remained unchanged during the course of 4 weeks in either the anakinra group (P = 0.44) or the placebo group (P = 0.33) ( Table 2) . White blood counts reversibly decreased by 0.915 g/L (95% CI, 21.397 to 20.435; P , 0.001) in the anakinra group compared with the placebo group ( Table 2) .
Hormones
Levels of calculated free testosterone did not significantly change in the total study population during 4 weeks, neither in the anakinra group (P = 0.35) nor in the placebo group (P = 0.30) ( Table 2) . However, patients with baseline CRP levels .2.0 mg/L showed an increase in calculated free testosterone levels of 0.06 nmol/L (95% CI, 0.01 to 0.10; P = 0.01), as compared with placebo. Likewise, patients with a BMI .40 kg/m 2 featured an increase in free testosterone levels upon anakinra treatment (between group difference 0.07 nmol/L; 95% CI, 0.01 to 0.12; P = 0.02).
Levels of SHBG were significantly increased during the course of 4 weeks, resulting in a between-group difference of 4.15 nmol/L (95% CI, 0.88 to 7.43; P = 0.01). There was no difference in estradiol levels between groups at 4 weeks (P = 0.99). LH and FSH levels, when regarded separately, were not changed in both groups, but anakinra administration was associated with a slight decrease of LH/FSH ratio, although not meeting statistical significance (between-group difference 20.12; 95% CI, 20.25 to 0.01; P = 0.06) ( Table 2; Supplemental Table 1) .
Among patients randomized to receive anakinra, serum levels of prolactin were consistently higher than in the placebo group. At 4 weeks, change in prolactin levels was 1.36 ng/mL (P = 0.002) in the anakinra group and 0.22 ng/mL (P = 0.61) in the placebo group (betweengroup difference, 1.06 ng/mL; 95% CI, 20.94 to 2.22; P = 0.07) ( Table 2; Supplemental Table 1 ).
Metabolic parameters
The changes in total cholesterol, HDL cholesterol, and LDL cholesterol, triglycerides, fasting glucose levels, and the insulin-sensitivity index, as calculated by homeostasis Figure 1 . Enrollment and outcomes. A total of 279 male patients with metabolic syndrome were recruited either in the outpatient clinics of the two participating centers or through newspaper advertisements. Of those, 81 patients did not respond, were not interested, or were not eligible on the basis of their medical history. Of the 198 patients who underwent physical and biochemical screening, 128 were found to be ineligible according to entry criteria, in most cases because they had either a total testosterone level of .12 nmol/L or a BMI ,30 kg/m 2 . Seventy patients were randomly assigned to receive either anakinra or placebo. In the anakinra group, one patient was excluded due to regular cannabis abuse that he concealed from the investigators at screening and one patient withdrew after 3 d of treatment due to extensive lipodystrophy from longstanding insulin treatment. In the placebo group one patient was excluded due to lower respiratory tract infection at day 1 with a CRP level of 49.2 mg/L. A total of 67 patients completed the 4-wk treatment and evaluation of study endpoints.
model assessment, did not differ between groups during 4 weeks (data not shown).
Clinical variables
Symptoms of hypogonadism
At baseline, self-reported severity of symptoms of hypogonadism as assessed by the qADAM score was not significantly different between groups, with a mean score of 31.9 6 4.1 in the placebo group and of 30.8 6 5.8 in the anakinra group (P = 0.39). Anakinra treatment was not associated with a benefit on the symptoms of hypogonadism over placebo (P = 0.55) ( Table 3) .
Sexual function
At baseline, men allocated to anakinra reported lower sexual function as assessed by the IIEF score 38.7 6 20.4 compared with 46.5 6 16.9 points in the placebo group (P = 0.06). At 4 weeks, the change from baseline in the IIEF score was 21.87 points (95% CI, 25.68 to 1.94) in the anakinra group, as compared with 2.41 points (95% CI, 21.64 to 6.45) in the placebo group, with no statistical difference between anakinra and placebo (difference, 25.31 points; 95% CI, 210.78 to 0.16; P = 0.06). (Table 3 ).
Fatigue
Both groups had pronounced improvements in motor and cognitive fatigue symptoms, without differences between the groups at 4 weeks ( Table 3) .
Body composition and grip strength
The two groups did not differ in the change from baseline in total body fat mass or lean body mass, as assessed with body impedance analysis (data not shown). Although patients did not have improvements in grip strength of the dominant hand, there was a significant increase by 3.5 kg (95% CI, 0.23 to 6.81; P = 0.04) in grip strength of the nondominant hand in the anakinra group, as compared with placebo (Table 3) .
Cardiovascular system
At 4 weeks, systolic blood pressure decreased by 3.90 mm Hg (95% CI, 27.59 to 20.21; P = 0.04) in the anakinra group, compared with a nonsignificant change of 1.01 mm Hg (95% CI, 21.88 to 3.89; P = 0.48) in the placebo group (between-group difference, 23.10 mm Hg; 95% CI, 27.37 to 1.18; P = 0.15). Anakinra treatment was associated with a change in diastolic blood pressure by 22.94 mm Hg (95% CI, 25.33 to 20.54; P = 0.02) compared with 0.80 mm Hg (95% CI, 21.47 to 3.07; P = 0.48) in the placebo group, with a trend toward lower diastolic blood pressure values (between-group difference, 22.70 mm Hg; 95% CI, 25.50 to 0.09; P = 0.06) ( Table 3) . Mean arterial blood pressure values likewise tended to be lower by 2.90 mm Hg in patients treated with anakinra (95% CI, 25.99 to 0.19; P = 0.07).
Adverse events
No patient withdrew from the study because of drugrelated adverse events. There were no severe and no unexpected adverse events related to the study drug anakinra. The most common side effect was injection-site reaction, which occurred in 21 patients (60%) receiving anakinra. In 10 patients (48%), the severity of these cutaneous side effects was reported to be interfering with daily activities (Table 4) .
In the anakinra group, the increase in total testosterone levels significantly differed between patients who had injection-site reactions and those who did not (Supplemental Appendix; Supplemental Fig. 3 ). There was an increase of 1.71 nmol/L (95% CI, 0.22 to 3.19; P = 0.03) in the total testosterone level in patients without injection-site reactions compared with 0.79 nmol/L (95% CI, 20.37 to 1.95; P = 0.17) in those with cutaneous adverse events.
Further endpoints
All predefined secondary endpoints at the time points 1 week and 3 months are summarized in the Supplemental Appendix in Supplemental Table 1 .
Discussion
The key finding of this proof-of-principle study is that in obese male patients with total testosterone levels ,12 nmol/L (346 ng/dL) and at least one component of the metabolic syndrome, anti-inflammatory treatment with anakinra was associated with a significant increase in total testosterone, with a between-group difference of 0.96 nmol/L (95% CI, 0.3 to 1.9; P = 0.04).
The treatment effect was most pronounced in patients with evidence of systemic inflammation at baseline, mirrored by elevated CRP levels. As further confirmation for the inflammatory hypothesis (9), increases in testosterone levels were most pronounced in patients who achieved an early reduction in CRP levels of .1 mg/L. This is also in line with data from the CANTOS trial, which showed that the extent of high-sensitivity CRP reduction upon IL-1 antagonism already after a single dose of canakinumab helped to identify individuals with the largest benefit from continued treatment concerning cardiovascular outcomes (23) . However, almost a third of patients included in our trial displayed baseline CRP levels ,2 mg/L and thus did not respond to antiinflammatory treatment. Lower effect sizes in these patients may have led to an underestimation of the overall effect size of IL-1 antagonism. Additionally, compared with the patients included in the T-Trials (24), our cohort included patients with only modestly reduced testosterone levels. There was an inverse association of baseline testosterone levels and both laboratory and clinical effects of IL-1 antagonism (data not shown), suggesting that patients with less severe testosterone deficiency were also less likely to achieve a benefit from IL-1 antagonism. The observed effects on total testosterone levels could be interpreted as the result of increased SHBG concentrations. However, pronounced elevations of SHBG would rather reduce the fraction of free testosterone due to higher binding capacity of circulating SHBG dimers. However, in subgroups of patients with higher systemic baseline inflammation (CRP .2 mg/L) or more pronounced obesity (BMI .40 kg/m 2 ) who showed the highest effect sizes of total testosterone increases, also levels of calculated free testosterone increased upon IL-1 antagonism, despite the changes in SHBG (Supplemental Appendix; Supplemental Figs. 4 and 5) . Hence, upon IL-1 antagonism an enhanced net testosterone production may be assumed. Importantly, neither body weight nor fat mass was altered after 4 weeks, and therefore increases in testosterone or SHBG were not due to weight reduction.
To investigate whether the effects on the hypothalamicpituitary-gonadal axis were mediated via central or rather peripheral mode of action, we analyzed several pituitary and peripheral hormones. Although there is experimental evidence that anakinra crosses the bloodbrain barrier (25, 26) and thus may antagonize the suppressive mechanisms of inflammatory mediators on LH secretion (11, 27) , we did not observe any rises in LH levels. Conversely, increased levels of prolactin in the anakinra group may have masked the anticipated rise in LH. In fact, previous studies have shown that both prolactin and cortisol secretion are dependent on systemic levels of IL-1b (20, 28) ; however, the underlying mechanisms have not been elucidated yet. Alternatively, IL-1 has been shown to be a potent inhibitor of testicular testosterone production (29, 30) , and therefore a direct disinhibitory effect on Leydig cell steroidogenesis may as well be postulated. Furthermore, because aromataseinduced conversion of testosterone to estradiol in adipose tissue has been shown to be enhanced in inflammatory states (31), we investigated effects on estradiol levels. Although there was a significant reduction of estradiol levels at 1 week of treatment, this effect was not sustained during the total treatment period. Based on our data it is therefore not possible to fully discriminate between central or peripheral effects and yet we assume a combination of both. The improvements on testosterone homeostasis did also translate into some clinical effects, which is remarkable considering the short treatment duration. Men who received anakinra had slightly reduced systolic and diastolic blood pressure values at 4 weeks of treatment. This is in line with previous clinical data (20) and experimental evidence indicating an antihypertensive effect of IL-1 antagonism via a nitric oxide-dependent mechanism (32, 33) . Furthermore, an improvement of muscle strength in the nondominant hand was observed, possibly due to increased endogenous testosterone levels (34), yet a diminished systemic inflammation could have exerted beneficial effects on muscle mass and strength as well (35) . However, it remains unclear why muscle strength of the dominant hand was not affected. Therefore, further studies are necessary to confirm the effects on muscle strength and to exclude a possible chance finding.
Anakinra treatment did not reduce the severity of symptoms of hypogonadism, nor domains of sexual function, nor the severity of fatigue; however, clinically meaningful effects on these symptom scales can arguably not be expected after a treatment duration of 4 weeks (36, 37) . However, it may be assumed that there was a placebo effect on qADAM and FSMC symptom scales, because significant improvements were observed both in anakinra and placebo groups. This is in line with data from previous trials that have shown comparable placebo effects (38, 39) . Although IL-1 antagonism is known to improve glucose metabolism in patients with established type 2 diabetes (14) , the large CANTOS trial did not show profound and sustained decreases in HbA1c in a cohort that was not designed to specifically test the effects on glucose control among patients with established diabetes (40) .
Mild adverse events, that is, injection site reactions with symptoms of erythema, pruritus, and pain, were relatively frequent in our study, presumably due to the dose of 200 mg daily. This observation is consistent with previous studies indicating a dose dependency of the occurrence and severity of injection-site reactions (41, 42) . The rationale for a dose of 200 mg/d comes from previous data where metabolic effects of anakinra were less pronounced in obese patients with higher body surface area (14) . In patients who developed skin reactions, the therapeutic effects on testosterone were diminished (Supplemental Appendix; Supplemental Fig. 3 ), because the severity of the inflammatory skin reactions were inversely correlated with reductions of CRP levels (43) . The availability of the long-acting canakinumab (15) with less skin reactions, rendering multiple daily injections unnecessary, might provide an attractive future alternative in the treatment of male hypogonadism.
Strengths of our study include the randomized, controlled, and double-blind design, the high accuracy and reproducibility of the measurement methods, and correlation of laboratory effects with clinical variables. Limitations that need to be considered include the short duration of treatment, inclusion of patients with only marginal systemic inflammation and only borderline low testosterone levels, as well as the relatively high frequency of injection-site reactions.
In conclusion, among middle-aged obese men with low testosterone levels, anakinra treatment increased endogenous testosterone levels. Observed effects on testosterone levels were proved without weight reduction. Although the treatment of choice in obese men with testosterone deficiency should clearly be lifestyle intervention, IL-1 antagonism could be a new and attractive treatment option taking into account the known favorable effects on glycemic control (14) , cortisol levels, and blood pressure (20) , as well as relevant cardiovascular outcomes (15) . Longer-term studies of IL-1 antagonists in patients with chronic low-grade inflammation will be needed to confirm and extend these findings. In one patient an elective follow-up after cervical spinal fusion revealed a misplacement of one spinal screw that had to be repositioned during the study period.
